Prof Stan Kaye discusses his two talks at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the current state of PARP inhibitors and anti-angiogenics. Research shows that cells with BRAC mutations, when exposed to Poly (ADP-ribose) polymerase, PARP, virtually dissolve. About 18 percent of ovarian cancer cases have this mutations, but up to half of patients will respond to these inhibitors. The difference in response comes from platinum sensitivity. Bevastusimab and other compounds show significant improvement to progression free and overall survival. Prof Kaye states that these different agents need to be fit into current treatment methods and other disease areas.